| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02215044 Details | 2014-08-13 Interventional | 1 | 12 | Gemcitabine Pancreatic Neop… | - - | |||
| NCT02145689 2013-002327-42 Details | 2014-08-13 Interventional | 3 | 0 | Botulinum Toxin… Botulinum Toxin… abobotulinumtox… Muscle Spastici… Stroke | The study was withdrawn prior to enrollment due to corporate decision. - | |||
| NCT02095574 Details | 2014-08-13 Interventional | 1 | 0 | Venetoclax Lymphoma Lymphoma, Non-H… Relapsed/Refrac… | This study will now be conducted in healthy volunteers. - | |||
| NCT00381017 2005-003876-39 Details | 2014-08-13 Interventional | 3 | 0 | Interferon alph… Interferon-alph… Interferons Peginterferon a… Hepatitis Hepatitis A Hepatitis C Liver Cirrhosis HIV Infections | Non-protocol feasibility - | |||
| NCT02214095 Details | 2014-08-12 Interventional | 1 | 40 | Anti-Inflammato… Chronic Periodo… Periodontitis | had been finished - | |||
| NCT01810575 Details | 2014-08-12 Interventional | 2 | 16 | Alprostadil Erectile Dysfun… | Re-assessment of study - | |||
| NCT01430585 Details | 2014-08-12 Interventional | 2 | 14 | Letrozole Breast Neoplasm… Advanced Breast… Early Breast Ca… | See termination reason in detailed description. Study was prematurely terminated due to PF-04691502 tolerability findings that prompted Sponsor to re-evaluate strategic goals of program. Unexpected frequency of severe skin toxicity was observed and no participant was enrolled in phase 2 of study. | |||
| NCT00265915 Details | 2014-08-12 Interventional | 2 | - | Rituximab Sargramostim Leukemia Leukemia, Lymph… Leukemia, Lymph… | - - | |||
| NCT01156051 NCT01153178 Details | 2014-08-11 Interventional | 4 | 29 | Guanfacine Attention Defic… Hyperkinesis Sleep Initiatio… Sleep Wake Diso… Attention Defic… Attention-Defic… Insomnia Sleep Disorders | extended beyond completion date; chose to close out rather than renew IRB review - | |||
| NCT00812435 Details | 2014-08-11 Interventional | 3 | 22 | Eptifibatide Infarction Myocardial Infa… | - - | |||
| NCT01499667 2011-001442-15 Details | 2014-08-08 Interventional | 3 | 142 | Fingolimod Hydr… Multiple Sclero… Multiple Sclero… Sclerosis Relapsing Remit… | Based on recent publications, determination of natalizumub washout period was no longer
relevant. Study was terminated due to new data on nataluzimab washout prior to treatment with other disease modifying treatments. The power to detect statistically significant differences between the washout groups based on the (-)binomial is estimated 30-40%. | |||
| NCT01318642 2010-023978-39 Details | 2014-08-08 Interventional | 2 | 10 | Gemcitabine Adenocarcinoma Adenocarcinoma … Locally Advance… Unresectable | NCT01318642: Planned independent DMC Interim review: ended for futility w/no safety concerns - | |||
| NCT01189253 2009-014889-26 Details | 2014-08-08 Interventional | 2/3 | 133 | Doxorubicin Liposomal doxor… Trabectedin Sarcoma | Results of step1: none of the experimental arms fulfills expectations and the study will not
continue as a phase III. - | |||
| NCT00911326 Details | 2014-08-08 Interventional | 3 | 101 | Dextrans Technetium Tc 9… Carcinoma Carcinoma, Squa… Squamous Cell C… Head and Neck S… | The trial was terminated early based on an interim review by the Data and Safety Monitoring
Committee for positive efficacy outcome and no safety concerns. The study was prospectively structured to include an interim analysis at 33.3% enrollment. The trial was terminated early based on an interim review by the Data and Safety Monitoring Committee for positive efficacy outcome and lack of safety concern. | |||
| NCT02149095 Details | 2014-08-07 Interventional | 1 | 0 | Treprostinil PAH | Study will not be conducted - | |||
| NCT02209701 Details | 2014-08-06 Interventional | 1 | 3 | Porfiromycin Head and Neck N… | - - | |||
| NCT01452347 2010-022685-27 Details | 2014-08-06 Interventional | 2 | 328 | Dabigatran Warfarin Heart Valve Dis… | - This study was terminated prematurely due to safety concerns arising during conduct of the trial. | |||
| NCT00944333 Details | 2014-08-05 Interventional | 3 | 1378 | Clopidogrel Angina Pectoris Ischemia Silent Ischemia | STOP due to recent data in literature questioning the need to continue DAP beyond six months in
patients with stable coronary artery stenting with DES. - | |||
| NCT01118663 Details | 2014-08-04 Interventional | 3 | 17 | Acetylcysteine Edetic Acid N-monoacetylcys… Pentetic Acid Drug Overdose Acetaminophen O… | - - | |||
| NCT01282047 2010-022898-33 Details | 2014-08-01 Interventional | 2 | 12 | Lenalidomide Acquired Immuno… Communicable Di… HIV Infections Infections Xeroderma Pigme… HIV Infection A… | - - |